Rigel Pharmaceuticals Inc. is projected to report third-quarter 2026 revenue of $80.10 million and a consensus EPS of $0.87, with shares currently trading near $50.74 against a mean analyst price target of $64.26.
Investors are primarily watching for the expansion of net product sales, specifically the performance of TAVALISSE and the initial commercial integration of VEPPANU following its landmark licensing deal earlier this year.
The company has maintained a trajectory of positive net income throughout 2026, driven by strong commercial execution in the hematology and oncology sectors. Management’s updates on the R289 IRAK1/4 inhibitor clinical trial will also be a key area of focus for future growth prospects.